The focus of the research in the Scott laboratory is aimed at improving outcomes of patients with lymphoid cancers through precision medicine. This involves unravelling the molecular determinants of treatment failure, applying cutting edge technology to patient biopsies, and then translating that knowledge into assays that can be used to guide treatment management. These approaches have led to the development of prognostic and predictive biomarkers for classical Hodgkin lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma that are applicable to routinely produced formalin-fixed paraffin-embedded biopsies – allowing these assays to be used in clinical practice. 

The poor outcomes seen when patients experience treatment failure have led to an emphasis on the biology of these cancers at the time point of relapse, exploring high-risk genetic features and evolution of tumors as they are exposed to immuno-chemotherapy. The Scott laboratory is now leading and co-ordinating correlative studies in clinical trials of treatment of relapsed and refractory aggressive B-cell lymphoma. Finally, the Scott laboratory has broadened the biobank at BC Cancer to enable the expansion of this research into chronic lymphocytic leukemia (CLL).

The translational focus of the Scott laboratory is made possible through collaborations within the BC Cancer’s Centre for Lymphoid Cancer with treating physicians and pathologists in Vancouver and across BC, along with Scientists at the BC Cancer Research Centre and the Genome Sciences Centre. The Scott laboratory is also part of international collaborative efforts, notably the Lymphoma/Leukemia Molecular Profiling Project (LLMPP) and the Lunenburg Lymphoma Biomarker Consortium (LLBC). Finally, and key to clinical translation, are the collaborations with Canadian (CCTG) and US (ECOG, Alliance andSWOG) clinical trials groups.




Kelly Mekwunye, MSc

Biospecimen Technician


Dr. Andrew Lytle

Postdoctoral Fellow


Open Positions

MSc/PhD Students - Scott Lab

Application Deadline

The Scott Lab is seeking highly motivated MSc and/or PhD students to work on the genomics of mature B-cell lymphomas. Principal Investigator Dr. David Scott is a renowned clinician scientist who has led international collaborations to improve classification and understanding of lymphomas. Our group has generated sequencing data from thousands of patient samples across many lymphoma types that are ready to be analyzed and published. Ongoing projects in the lab are going beyond traditional omics to deepen our understanding of aggressive lymphomas through single-cell multi-omics, long-read Oxford Nanopore sequencing and DNA methylation analyses, and spatial imaging and sequencing technologies, working at the cutting edge of translational cancer research. We are generously funded through organizations such as the Terry Fox Research Institute, Genome BC, BC Cancer Foundation, Lymphoma Research Foundation, and the NIH. 

As part of the Centre for Lymphoid Cancer, the Scott Lab collaborates closely with many clinicians and scientists with diverse research programs. Trainees are involved in all stages of their project, including planning, development, and collaboration.  All trainees have opportunities to present in internal seminar series and are encouraged to attend and present at international conferences. Students will enrol in the UBC Pathology and Laboratory Medicine or Interdisciplinary Oncology (IOP) graduate programs. 

The ideal candidate would have demonstrated experience and/or aptitude in bioinformatics, genomics, and statistics. Experience programming in R and/or Python would be an asset but not required. Interested applicants should send a cover letter and CV to: and

This is an ongoing posting and applications are welcome any time. 

Selected Publications


Overcoming Treatment Failure in Lymphoid Cancer (TFRI-funded Program)

This team grant is a collaborative effort, which experts in lymphoid cancer biomarkers and tumor microenvironment, hematology and cancer genomics jointly aim to understand and overcome treatment failure in lymphoid cancers. The team will identify and validate target-specific molecular tests characterizing genetic changes and molecular pathways which provide the preclinical rationale for novel drug development.

Large-Scale Applied Research Project (LSARP Program)

Dr. Steidl and Scott teams have successfully won a large-scale applied research project worth $11.9 million funded by Genome Canada, Genome BC, Canadian Institutes of Health Research and BC Cancer Foundation to study the genome biology of relapsed lymphoid cancers. Our large-scale, pan-Canadian study was launched last year to discover novel, actionable markers of relapsed lymphoma from which clinically relevant assays can be developed.

Back to top